Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Lorcaserin in Obese Adolescents
NCT02022956Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lorcaserin in obesity, sponsored by Eisai Co., Ltd. Primary endpoints: Pharmacokinetic parameters of lorcaserin and metabolites (M1 and M5) at 96 hours and Safety and tolerability of a single oral dose of lorcaserin at 96 hours. Started Dec 2013; status: completed.
02
Drugs
lorcaserin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02022956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02022956.